Together, we conclude that ENPP1 is an innate immune checkpoint restraining STING pathway activation in the tumor microenvironment (TME) and that therapeutically targeting ENPP1’s cGAMP hydrolysis activity could dramatically increase the number of patients who completely respond to anti-PD-1 therapies. The gene discussed is STING1; the disease is neoplasm.